Biogen

US · BIIB #623 by market cap Listed 1970

222.15 -0.74 -0.33%

Live - 5344 symbols - heartbeat 56s ago · 2026-10-08 04:46

Pre-market 222.80 +0.29%

After-hours 222.15 0.00%

Overnight 221.74 -0.18%

Market cap: 32.82B
P/E (TTM): 39.46
P/B: 1.74
EPS: 8.79
Div yield: 0.00%
52W pos: 91%

Reader sentiment Are you bullish or bearish on BIIB?

Anonymous reader poll. Unscientific, not investment advice.

About Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Founded: 1978
CEO: Mr. Christopher A. Viehbacher
Employees: 7,500
Headquarters: Cambridge, Massachusetts, United States of America
Fiscal year end: 12-31
Website: biogen.com

Company profile

Exchange: US
Symbol: BIIB
Market-cap rank: #623
Listing date: 1970-01-01
Market cap: 32.82B
Float cap: 32.70B
Shares out: 147.75M
Float shares: 147.22M

Sectors & themes

Cancer Research Drug Manufacturers - General Global medical industry Regular Savings Plan Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 04:46:37 · For reference only, not investment advice and not tailored to your situation.